Beth Faiman PhD

I put together a free guide on using AI the right way in medicine. How to use it as a teacher. Where the ethical line is. 45+ research databases. Formal AI courses from AMA, AAMC, Harvard, Stanford. For medical students, IMGs, residents, and fellows: linkedin.com/posts/faiz-anw…

@AJPortuguese @RahulBanerjeeMD @BloodCancerJnl So I have to say I’m a bit surprised by this. This is a much lower PFS then I would have anticipated. 50% exposed to Bcma, the majority is CART and not another bcma bite. And even in trial eligible pts median pfs <7 months. Disappointing :(

Fascinating - albeit a little terrifying - @LeukemiaJnl work by 🇩🇪 How does GPRC5D loss affect surviving myeloma #MMsm clones? Here, remaining cells appear to be more aggressive. Will be important to validate / rebut as talquetamab moves into earlier lines... hopefully soon!

Small n, as authors note... looking forward to validation! Ophtho requirement before each dose creates barriers; unclear ∆ value vs just asking pt. Hopefully bela-maf REMS goes way of CAR-T REMS some day! Link to @BloodPortfolio article (excellent commentary by @szusmani et al): ashpublications.org/blood/article/…

Excellent 🇬🇷 Bela-Rd IIT by Terpos et al, now in @BloodPortfolio I particularly loved this randomization: ophtho-graded vs pt-graded 👁️ bela-maf AEs using 9-question VRA survey. Time to Gr2+ AE resolution same (1.8 mo) in both groups... Pt surveys the way to go in future? 🤔

The IMF makes getting updates about multiple myeloma both easy and accessible. Make sure you stay up to date and don't miss any future events. Visit subscribe.myeloma.org to make sure you're on the newsletter list! #AsktheIMF @Bethfaiman @jmikhaelmd

Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH) [Apr 2, 2026] @MKaddouraMD et al. @lbaughn @BloodPortfolio ashpublications.org/blood/article/… #mmsm #PrecisionMedicine

New publication 📝 Real-world data, published in @BloodPortfolio, reported a 34% early mortality rate within 12 months of bsAb therapy initiation in patients with relapsed/refractory #MultipleMyeloma. Learn more: bit.ly/4uTy8QU #myeloma #mmsm #MedNews #MedEd

New in Blood (April 2, 2026): "Genomic mechanisms of resistance to venetoclax in t(11;14) myeloma" — Kaddoura, Kumar, Maura, Baughn et al. We know venetoclax works in t(11;14) myeloma. What we haven't understood well is why some t(11;14) patients don't respond — or respond then progress quickly. This paper starts to answer that with whole-genome/exome sequencing of 34 patients. Study link: doi.org/10.1182/blood.…

The International Myeloma Foundation is here for you! Attend a free patient event: events.myeloma.org Connect with the IMF InfoLine to get your questions answered: myeloma.org/infoline Ask Myelo your questions any time at myeloma.org #AsktheIMF @jmikhaelmd

Didn't match this cycle? It's not the end, it's a reset. Every IMG who kept trying eventually matched. You only lose when you stop. Full playbook 👇 linkedin.com/posts/faiz-anw… #IMG #Match2026 #Residency

Can dexamethasone cause abdominal changes? Myeloma expert Dr. @jmikhaelmd answers in this short clip. Watch the experts answer your myeloma questions in the full Q&A at myeloma.org/node/12840 #AsktheIMF @Bethfaiman

Myeloma Signals – March 2026 🧬 Not just new drugs. A shift in how we think. 1️⃣ Immunotherapy moving earlier (MajesTEC-9) → Works best before T-cell exhaustion 2️⃣ CELMoD era arrives (SUCCESSOR-2) → Not another IMiD… a new backbone 3️⃣ Toward cure → The best chance to cure may be EARLY disease The big idea: Myeloma is moving from “Which drug next?” ➝ “When do we strike?” Earlier Deeper With intent to eradicate #myeloma #smmm #hemetwitter

#Myeloma Paper of the Day: Clinical risk models remain relevant for #Waldenström pts receiving non-BTKi therapy, but molecular features, especially MYD88, CXCR4 & TP53 mutations provide superior prognostic insights for pts w/ BTKi-based regimens: pubmed.ncbi.nlm.nih.gov/41912911/. #mmsm

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd

Lead guitarist of The Plasma Cells! @JoshuaRichterMD

@JoshuaRichterMD ❤️❤️

Sunday noodling 🤘🤘🤘

What is considered a low dose of dexamethasone? Myeloma expert and IMF Nurse Leadership Board member @Bethfaiman answers in this short video. Watch the experts answer your myeloma questions in the full Q&A: myeloma.org/node/12840 #AsktheIMF @jmikhaelmd

A Real-World Study of Tafasitamab for Relapsed/Refractory DLBCL Clinical trials tell us what’s possible— real-world data tell us what actually happens. Tafasitamab + lenalidomide in practice: 📊 ORR ~73% ⏳ PFS ~11 months 📈 OS ~25 months But here’s the key insight 👇 Earlier use matters. 2nd-line therapy → better outcomes Later lines → higher risk of progression and death This isn’t just validation— it’s a signal about how we should be sequencing therapy in DLBCL. Real-world evidence is catching up to strategy 🧠 onlinelibrary.wiley.com/doi/pdf/10.100… #OncTwitter #DLBCL #Lymphoma #CAR-T #Immunotherapy

@VincentRK @szusmani @ACPIMPhysicians @AnnalsofIM Thank you for sharing! See my Mar/Apr 26 @JADPRO editorial which addresses this paper. Physicians, nurses, pharmacists and others should be called by their appropriate titles but may have overlapping roles thus provides a challenge when referring to groups in aggregate @APSHOorg

Doctor, not provider. @ACPIMPhysicians @AnnalsofIM acpjournals.org/doi/10.7326/AN…